Loading...
XNAS
EMBC
Market cap683mUSD
Dec 05, Last price  
11.69USD
1D
0.09%
1Q
-21.86%
IPO
-61.67%
Name

Embecta Corp

Chart & Performance

D1W1MN
XNAS:EMBC chart
P/E
8.74
P/S
0.61
EPS
1.34
Div Yield, %
5.13%
Shrs. gr., 5y
0.46%
Rev. gr., 5y
0.25%
Revenues
1.12b
+0.21%
1,109,000,0001,085,500,0001,165,000,0001,129,500,0001,120,800,0001,123,100,000
Net income
78m
+11.22%
432,000,000427,600,000414,800,000223,600,00070,400,00078,300,000
CFO
36m
-47.27%
505,000,000498,500,000456,000,000412,200,00067,700,00035,700,000
Dividend
Aug 27, 20240.15 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
IPO date
Mar 21, 2022
Employees
1,900
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT